Found: 91
Select item for more details and to access through your institution.
Clonal expansions of CD8 T cells in latently HSV-1-infected human trigeminal ganglia.
- Published in:
- Journal of NeuroVirology, 2012, v. 18, n. 1, p. 62, doi. 10.1007/s13365-011-0067-9
- By:
- Publication type:
- Article
Control of HSV-1 latency in human trigeminal ganglia-current overview.
- Published in:
- Journal of NeuroVirology, 2011, v. 17, n. 6, p. 518, doi. 10.1007/s13365-011-0063-0
- By:
- Publication type:
- Article
The prevalence of human herpesvirus 6 in human sensory ganglia and its co-occurrence with alpha-herpesviruses.
- Published in:
- Journal of NeuroVirology, 2007, v. 13, n. 5, p. 462, doi. 10.1080/13550280701447059
- By:
- Publication type:
- Article
Cell-binding IgM in CSF is distinctive of multiple sclerosis and targets the iron transporter SCARA5.
- Published in:
- Brain: A Journal of Neurology, 2024, v. 147, n. 3, p. 839, doi. 10.1093/brain/awad424
- By:
- Publication type:
- Article
Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Expression of the Antioxidative Enzyme Peroxiredoxin 2 in Multiple Sclerosis Lesions in Relation to Inflammation.
- Published in:
- International Journal of Molecular Sciences, 2017, v. 18, n. 4, p. 760, doi. 10.3390/ijms18040760
- By:
- Publication type:
- Article
B Cells and Autoantibodies in Multiple Sclerosis.
- Published in:
- International Journal of Molecular Sciences, 2015, v. 16, n. 7, p. 16576, doi. 10.3390/ijms160716576
- By:
- Publication type:
- Article
Latency of herpes simplex virus type-1 in human geniculate and vestibular ganglia is associated with infiltration of CD8+ T cells.
- Published in:
- Journal of Medical Virology, 2010, v. 82, n. 11, p. 1917, doi. 10.1002/jmv.21904
- By:
- Publication type:
- Article
Prevalence and distribution of HSV‐1, VZV, and HHV‐6 in human cranial nerve nuclei III, IV, VI, VII, and XIIDiethide Theil and Anja KE Horn contributed equally to this work.
- Published in:
- Journal of Medical Virology, 2004, v. 74, n. 1, p. 102
- By:
- Publication type:
- Article
PARP-1 deregulation in multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2019, v. 5, n. 4, p. 1, doi. 10.1177/2055217319894604
- By:
- Publication type:
- Article
Unraveling natalizumab effects on deregulated miR-17 expression in CD4+ T cells of patients with relapsing-remitting multiple sclerosis.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4<sup>+</sup> T Cells of Patients with Relapsing-Remitting Multiple Sclerosis.
- Published in:
- Journal of Immunology Research, 2014, p. 1, doi. 10.1155/2014/897249
- By:
- Publication type:
- Article
Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa.
- Published in:
- Clinical Chemistry & Laboratory Medicine, 2016, v. 54, n. 10, p. 1655, doi. 10.1515/cclm-2015-1195
- By:
- Publication type:
- Article
Recommendations for the Use of Prolonged-Release Fampridine in Patients with Multiple Sclerosis ( MS).
- Published in:
- CNS Neuroscience & Therapeutics, 2013, v. 19, n. 5, p. 302, doi. 10.1111/cns.12101
- By:
- Publication type:
- Article
Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2024, p. 1, doi. 10.1177/17562864241277736
- By:
- Publication type:
- Article
Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2023, p. 1, doi. 10.1177/17562864221150312
- By:
- Publication type:
- Article
Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2023, p. 1, doi. 10.1177/17562864221150040
- By:
- Publication type:
- Article
Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2023, v. 16, p. 1, doi. 10.1177/17562864221150312
- By:
- Publication type:
- Article
Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2023, v. 16, p. 1, doi. 10.1177/17562864221150040
- By:
- Publication type:
- Article
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper).
- Published in:
- Therapeutic Advances in Neurological Disorders, 2021, p. 1, doi. 10.1177/17562864211039648
- By:
- Publication type:
- Article
The Presence of Lytic HSV-1 Transcripts and Clonally Expanded T Cells with a Memory Effector Phenotype in Human Sensory Ganglia.
- Published in:
- Annals of the New York Academy of Sciences, 2009, v. 1164, p. 300, doi. 10.1111/j.1749-6632.2009.03871.x
- By:
- Publication type:
- Article
Escalating to medium‐ versus high‐efficacy disease modifying therapy after low‐efficacy treatment in relapsing remitting multiple sclerosis.
- Published in:
- Brain & Behavior, 2024, v. 14, n. 5, p. 1, doi. 10.1002/brb3.3498
- By:
- Publication type:
- Article
All Bruton's tyrosine kinase inhibitors have similar efficacy and risks: Commentary.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1502, doi. 10.1177/13524585221097562
- By:
- Publication type:
- Article
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 9, p. 1424, doi. 10.1177/13524585211069068
- By:
- Publication type:
- Article
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 3, p. 429, doi. 10.1177/13524585211024997
- By:
- Publication type:
- Article
Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 1, p. 132, doi. 10.1177/13524585211005339
- By:
- Publication type:
- Article
Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 3, p. 439, doi. 10.1177/1352458520918489
- By:
- Publication type:
- Article
Aggressive multiple sclerosis (1): Towards a definition of the phenotype.
- Published in:
- Multiple Sclerosis Journal, 2020, v. 26, n. 9, p. 1031, doi. 10.1177/1352458520925369
- By:
- Publication type:
- Article
Aggressive multiple sclerosis (2): Treatment.
- Published in:
- Multiple Sclerosis Journal, 2020, v. 26, n. 9, p. 1045, doi. 10.1177/1352458520924595
- By:
- Publication type:
- Article
A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence.
- Published in:
- Multiple Sclerosis Journal, 2019, v. 25, n. 12, p. 1682, doi. 10.1177/1352458519852100
- By:
- Publication type:
- Article
PML with dimethyl fumarate—No convincing case against natalizumab.
- Published in:
- 2019
- By:
- Publication type:
- Letter
Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2018, v. 24, n. 12, p. 1605, doi. 10.1177/1352458517728343
- By:
- Publication type:
- Article
Extensive bilateral brain lesions in neuromyelitis optica spectrum disorders.
- Published in:
- 2018
- By:
- Publication type:
- Letter to the Editor
Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing–remitting multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2018, v. 24, n. 6, p. 777, doi. 10.1177/1352458518768433
- By:
- Publication type:
- Article
Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop.
- Published in:
- Multiple Sclerosis Journal, 2018, v. 24, n. 5, p. 590, doi. 10.1177/1352458516686847
- By:
- Publication type:
- Article
Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity.
- Published in:
- Multiple Sclerosis Journal, 2016, v. 22, n. 12, p. 1550, doi. 10.1177/1352458515623365
- By:
- Publication type:
- Article
A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.
- Published in:
- Multiple Sclerosis Journal, 2015, v. 21, n. 7, p. 885, doi. 10.1177/1352458514554052
- By:
- Publication type:
- Article
MiR-126: a novel route for natalizumab action?
- Published in:
- Multiple Sclerosis Journal, 2014, v. 20, n. 10, p. 1363, doi. 10.1177/1352458514524998
- By:
- Publication type:
- Article
Interferon Beta and Vitamin D Synergize to Induce Immunoregulatory Receptors on Peripheral Blood Monocytes of Multiple Sclerosis Patients.
- Published in:
- PLoS ONE, 2014, v. 9, n. 12, p. 1, doi. 10.1371/journal.pone.0115488
- By:
- Publication type:
- Article
Cerebellar Abnormalities Contribute to Disability Including Cognitive Impairment in Multiple Sclerosis.
- Published in:
- PLoS ONE, 2014, v. 9, n. 1, p. 1, doi. 10.1371/journal.pone.0086916
- By:
- Publication type:
- Article
Glatiramer Acetate Treatment Normalizes Deregulated microRNA Expression in Relapsing Remitting Multiple Sclerosis.
- Published in:
- PLoS ONE, 2011, v. 6, n. 9, p. 1, doi. 10.1371/journal.pone.0024604
- By:
- Publication type:
- Article
Fingolimod for Multiple Sclerosis: Mechanism of Action, Clinical Outcomes, and Future Directions.
- Published in:
- Current Neurology & Neuroscience Reports, 2011, v. 11, n. 5, p. 492, doi. 10.1007/s11910-011-0216-9
- By:
- Publication type:
- Article
Intrathecal antibody (IgG) production against human herpesvirus type 6 occurs in about 20% of multiple sclerosis patients and might be linked to a polyspecific B–cell response.
- Published in:
- Journal of Neurology, 2005, v. 252, n. 8, p. 968, doi. 10.1007/s00415-005-0794-z
- By:
- Publication type:
- Article
Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury.
- Published in:
- Journal of Molecular Medicine, 2010, v. 88, n. 8, p. 753, doi. 10.1007/s00109-010-0632-3
- By:
- Publication type:
- Article
Potent neutralization by monoclonal human IgM against SARS‐CoV‐2 is impaired by class switch.
- Published in:
- EMBO Reports, 2022, v. 23, n. 7, p. 1, doi. 10.15252/embr.202153956
- By:
- Publication type:
- Article
Antigen Extraction and B Cell Activation Enable Identification of Rare Membrane Antigen Specific Human B Cells.
- Published in:
- Frontiers in Immunology, 2019, p. N.PAG, doi. 10.3389/fimmu.2019.00829
- By:
- Publication type:
- Article
Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis: A Systematic Review.
- Published in:
- JAMA Neurology, 2023, v. 80, n. 11, p. 1232, doi. 10.1001/jamaneurol.2023.3331
- By:
- Publication type:
- Article
Time to Change the Current Clinical Classification of Multiple Sclerosis?
- Published in:
- 2023
- By:
- Publication type:
- Opinion
Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.
- Published in:
- JAMA Neurology, 2019, v. 76, n. 3, p. 274, doi. 10.1001/jamaneurol.2018.4239
- By:
- Publication type:
- Article
Anti–Myelin Oligodendrocyte Glycoprotein Antibody–Associated Central Nervous System Demyelination—A Novel Disease Entity?
- Published in:
- 2018
- By:
- Publication type:
- Opinion